David Jensen

Writing from the perspective of more than three decades in the news business, Jensen brings a background in business and government to bear on the $3 billion California stem cell agency. Now retired, his career included a 10-year stint as executive business editor of The Sacramento Bee, legislative coverage for United Press International and two years as a press aide to Gov. Jerry Brown during his first term in office. Jensen has covered the stem cell agency since its inception from his sailboat/home located south of the border with visits to California from time to time.

Web Site: http://californiastemcellreport.blogspot.com/

Coming Up: Live Coverage of Thursday’s California Stem Cell Board Meeting

Jul 22, 2014

The California Stem Cell Report will provide live, gavel-to-gavel coverage of this Thursday’s meeting of the 29 members of the governing board of the $3 billion California stem Cell agency, which is expected to lop $15 million from its ambitious Alpha stem cell clinic proposal.

Interested parties in Canada will be able to participate...

California Stem Cell CEO Randy Mills on Focus and Four-Part Tests

Jul 22, 2014

It was a case of CEOs interviewing CEOs.

More specifically, it was Robin Smith, head of Neostem, Inc., “grilling” Randy Mills, the new CEO of the $3 billion California stem cell agency. The venue was the Huffington Post.

It wasn’t exactly hard ball stuff, as one might expect. Nonetheless it was the lengthiest such exchange with Mills, the former...

Verastem Bid for Nearly $10 Million from California Nixed

Jul 21, 2014

A Massachusetts firm called Verastem, Inc., heard some bad news recently about its pitch for $9.9 million from the $3 billion California stem cell agency.

The Cambridge firm sought the cash from the agency to help out with a clinical trial dealing with breast cancer.

However, the agency’s directors were told in...

Scripps Confirms Marletta’s Plan to Leave as President

Jul 21, 2014

The Scripps Research Institute has confirmed the departure of Michael Marletta as its president in a 72-word statement, but details about who will replace him and when are yet to emerge.The move was announced this morning at a meeting at the 2,900-empl...

Scrips Research President Resigns Following Financial Problems at the Institute

Jul 21, 2014

Michael Marletta today resigned as head of The Scripps Research Institute, one of nation’s leading biomedical research organizations, in the wake of an aborted, $600 million merger with the University of Southern California.

Bradley Fikes and Gary Robbins of the San Diego U-T reported that the announcement of his resignation came at a...

California’s Far-Reaching Alpha Stem Cell Clinic Plan Likely to Take Big Hit

Jul 21, 2014
California’s Far-Reaching Alpha Stem Cell Clinic Plan Likely to Take Big Hit

The new president of the California stem cell agency today recommended slashing $15 million from the agency’s ambitious Alpha stem cell clinic plan, declaring that the proposal’s $70 million cost is “not clearly justified.”

If the agency’s board goes along with the recommendation at Thursday’s meeting, it will be the first time the $3...

Creating Critical Mass at a California Stem Cell Consortium

Jul 20, 2014

News about the California stem cell agency is dominated by such matters as $70 million Alpha stem cell rounds and clinical trials but other significant activities occur below that high level surface.

One such event is the creation of a state-of-the-art imaging facility at the Sanford Consortium in the San Diego, a facility that...

Los Angeles Times: California Stem Cell Agency Rife with Conflicts and Unrealistic Expectations

Jul 19, 2014

The Los Angeles Times, California’s largest circulation newspaper, is carrying a piece this weekend about “cronyism,” conflicts of interest and “inflated expectations” at the state’s $3 billion stem cell agency.

The column by Pulitzer Prize-winning writer and author Michael Hiltzik used this month’s Trounson Affair as a starting point to dissect the situation...

California-funded Stem Cell Diabetes Treatment Edges Forward

Jul 18, 2014

CIRM video

The California stem cell agency’s $39 million investment in a possible therapy for diabetes moved forward this week with the announcement that the treatment could enter clinical trials as early as next month.

ViaCyte, a San Diego, Ca., firm, and the agency announced yesterday that the firm has applied with the FDA to...

StemCells, Inc., Says Patient Endangerment Charges Lack Merit

Jul 16, 2014

StemCells, Inc., said late today that charges that is endangering patients in clinical trials have no merit and that the company’s primary concern is the safety of its patients.

The Newark, Ca., company was responding to a lawsuit filed earlier this week that alleges the firm is manufacturing human cells in a process that...

Stay connected to Sacramento Connect

Follow Sacramento Connect on Twitter  Find Sacramento Connect on Facebook  Sign up for the Sacramento Connect Newsletter



  • Hot Topics (2)
  • Shopping (790)
  • Top Stories (3424)